Publicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (19)

2024

  1. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

  2. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry

    Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145

  3. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology

2023

  1. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  2. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

  3. SEOM 2022 clinical guidelines

    Clinical and Translational Oncology

  4. SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731

  5. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

  6. The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer

    Oncologist, Vol. 28, Núm. 10, pp. E902-E909

2022

  1. SEOM clinical guidelines (2021)

    Clinical and Translational Oncology

  2. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    ESMO Open, Vol. 7, Núm. 3

2020

  1. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 734-750

2018

  1. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis

    Journal of Geriatric Oncology, Vol. 9, Núm. 3, pp. 254-264

2017

  1. Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunction

    Clinical Respiratory Journal, Vol. 11, Núm. 6, pp. 859-866

2014

  1. Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1

    BMC Pulmonary Medicine, Vol. 14, Núm. 1

2006

  1. Does induction chemotherapy still have a role in larynx preservation strategies? The experience of institut catala d'oncologia in stage III larynx carcinoma

    Laryngoscope, Vol. 116, Núm. 9, pp. 1651-1656

2004

  1. Treatment of malignant superior vena cava syndrome by endovascular stent insertion: Experience on 52 patients with lung cancer

    Lung Cancer, Vol. 43, Núm. 2, pp. 209-214

2000

  1. Meningeal carcinomatosis as a cause of partially reversible blindness

    Clinical and Translational Oncology

1997

  1. CDC group IV c-2 infection in a stem cell transplant recipient

    Bone Marrow Transplantation, Vol. 20, Núm. 11, pp. 1005-1006